Business Context and Reporting Period
This Form 8-K Current Report, dated August 15, 2011, pertains to AngioDynamics, Inc., a medical device company. The filing reports the entry into a material definitive agreement and the appointment of a new Chief Executive Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Appointment
On August 15, 2011, the Board of Directors appointed Joseph M. DeVivo as President and Chief Executive Officer, effective September 7, 2011. Mr. DeVivo previously served as Global President of Smith & Nephew Orthopedics and as CEO of RITA Medical Systems (acquired by AngioDynamics in 2007).
Compensation and Contractual Terms
- Base Salary: $555,000 per year.
- Annual Bonus: Target level of 100% of base salary.
- Equity Grant: Options to purchase 400,000 shares and 25,000 restricted shares, vesting in four equal annual installments.
- Sign-on and Relocation Benefits: Includes a $200,000 housing allowance, up to $60,000 in relocation expenses, up to $10,000 for legal fees, and a $1,500 monthly car allowance.
- Severance (Termination without Cause/Good Reason): 24 months of base salary plus a lump sum equal to two times the prior year's cash bonus during the initial term.
- Change in Control Severance: 2.5 times annual base salary plus unpaid/prorated bonus and unused vacation if terminated following a Change in Control.
Investor Verification Checklist
- Verify the exact grant date and exercise price for the 400,000 stock options and 25,000 restricted shares, which are tied to the closing price on the grant date (anticipated September 7, 2011).
- Review the full text of Exhibit 10.1 (Employment Agreement) and Exhibit 10.2 (Change in Control Agreement) for specific definitions of "Cause" and "Good Reason."
- Confirm the impact of the $200,000 housing allowance and other sign-on costs on the company's immediate cash flow and expense recognition.
- Assess the potential dilution impact of the 425,000 total equity units granted to the new CEO.